These drugs could be alternatives for NSCLC treatment of patients with MET mutations and/or EGFR-TKI resistance, resulting in improvements in the way patients with NSCLC are treated, their survival, and their quality of life during and after treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.